Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., Christos, P. J., Saxena, A., Elemento, O., Bhinder, B., Ager, C., Amin, A. D., Sanfilippo, N. J., Mittal, V., Borczuk, A. C., … McGraw, T. E. (2023). Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44195-x